Skip to main content
Premium Trial:

Request an Annual Quote

Protagen, Bayer Schering Evaluate UNIarray Technology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German protein analysis and diagnostics firm Protagen and Bayer Schering Pharma today announced the closing of a cooperation contract for the discovery of biomarkers for endometriosis.

Terms of the deal were not disclosed.

The goal of the collaboration between the two firms is to evaluate the ability of Protagen's UNIarray technology to discover autoantibody patterns for the predictive diagnosis of endometriosis, which affects about 5 percent to 10 percent of women worldwide, Protagen said in a statement.

The current gold standard of diagnosis for the disease is laparoscopy, but "proteomic profiling of inflammation, angiogenesis, and tissue remodeling processes are becoming increasingly important to understand the biology of endometriosis," Protagen said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.